Harvard Management Company’s Seres Therapeutics MCRB Stock Holding History

Harvard Management Company’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-6,592	Closed	-$314K	–	16
2023 Q3	$314K	Hold	6,592	–	–	0.04%	22
2023 Q2	$632K	Hold	6,592	–	–	0.06%	30
2023 Q1	$748K	Hold	6,592	–	–	0.08%	42
2022 Q4	$738K	Hold	6,592	–	–	0.09%	41
2022 Q3	$846K	Hold	6,592	–	–	0.11%	44
2022 Q2	$452K	Hold	6,592	–	–	0.05%	43
2022 Q1	$939K	Hold	6,592	–	–	0.09%	43
2021 Q4	$1.1M	Hold	6,592	–	–	0.1%	43
2021 Q3	$918K	Hold	6,592	–	–	0.05%	38
2021 Q2	$3.15M	Hold	6,592	–	–	0.18%	33
2021 Q1	$2.71M	Hold	6,592	–	–	0.15%	36
2020 Q4	$3.23M	Buy	+6,592	New	+$3.86M	0.18%	24

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Harvard Management Company's MCRB Position: Q4 2023 in Review

Harvard Management Company sold out of Seres Therapeutics (MCRB) in Q4 2023, closing a stake of 6,592 shares — an estimated $314K sold.

Harvard Management Company first reported a position in MCRB in Q4 2020 and held it in 12 quarters. The position peaked at $3.23M in Q4 2020. 102 funds tracked by Wall St. Rank hold MCRB as of Q4 2023.

Harvard Management Company reported no remaining Seres Therapeutics position as of Q4 2023 after selling out during the quarter.
Harvard Management Company sold 6,592 Seres Therapeutics shares in Q4 2023, an estimated $314K.
Harvard Management Company first reported a position in Seres Therapeutics in Q4 2020 and held it in 12 quarters.
Harvard Management Company's Seres Therapeutics position peaked at $3.23M in Q4 2020.
102 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2023.

Based on Harvard Management Company's 13F filing for Q4 2023, filed 9 Feb 2024.